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Summary The question of whether initial prognostic factors in small-cell lung cancer patients have a
predictive value for patients' quality of life (QL) during chemotherapy is addressed in the context of a
randomised clinical trial comparing early and late alternating chemotherapy (SAKK protocol 15/84). The
relative impact of initial tumour stage and performance status, previous weight loss, sex and age on patient-
rated QL was analysed over six chemotherapy cycles in 124- 130 patients (according to available QL data) with
more than 400 questionnaires. Fatigue/malaise, personal functioning, emotional and general well-being were
prospectively selected as QL indicators. Predefined summary measures (average QL score over chemotherapy
cycles, 'minimum', 'maximum' and 'final' improvement) were analysed separately by scale in various patient
groups. General linear models adjusted for treatment arm and response were used to confirm the univariate
findings. Within the overall sample, the average QL scores over six cycles were predicted by initial prognostic
factors. Patients with poor prognostic factors reported worse QL. Within a limited sample (with baseline QL),
patients with poor prognostic factors reported worse QL at baseline and greater improvement under treatment.
Graphical comparison of QL patterns over cycles showed permanent discrimination by levels of prognostic
factors. The impact of initial prognostic factors was consistently confirmed in the three analyses. Levels of
performance status and weight loss best discriminated QL. Initial tumour stage, performance status and
previous weight loss can predict QL in small-cell lung cancer during chemotherapy, even after controlling for
response to treatment. Our results may contribute to clinical decision-making with regard to the intensity of
chemotherapy and QL outcome, especially in patients with extensive disease.
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Small-cell lung cancer (SCLC) remains a therapeutic
challenge, from both a biomedical and quality of life point
of view. The majority of patients respond to combination
chemotherapy resulting in a four- to 5-fold prolongation of
median survival, but only a small proportion survive disease-
free over a period of more than 2 years. In responders, early
chemotherapy is expected to have a beneficial impact on
physical functioning and subjective well-being by alleviation
of tumour symptoms.
However, the majority of patients who initially respond to
treatment will become refractory to therapy and die of their
disease. In clinical decision-making, the evaluation of the
trade-off between a potential gain in survival time and a
potential loss in quality of life (QL) owing to treatment
toxicity is a subtle task (Bergman and Aaronson, 1995). For
biomedical outcome, well-established prognostic factors
facilitate decision-making. In contrast, for QL outcome, no
systematic data on prognostic factors are, to our knowledge,
available.
It can be anticipated that QL is substantially predicted by
biomedical as well as psychosocial variables, such as the
coping process, social support and psychiatric history
(Bernhard and Ganz, 1995). These need more investigation,
and would require a standard assessment to be systematically
included in trials to improve decision-making. As a result of
the prognostic value of biomedical factors for survival, it is of
particular interest to evaluate whether they also predict QL
outcome, i.e. whether better (worse) initial prognostic factors
are a priori associated with better (worse) QL under
chemotherapy. We investigated the predictive value of
tumour stage, performance status, previous weight loss, sex
and age at diagnosis for QL during chemotherapy in a
controlled clinical trial (SAKK protocol 15/84) comparing
early and late alternating chemotherapy (Joss et al., 1995b).
Different methods for examining and analysing long-
itudinal QL data are presented. As suggested by the Medical
Research Council (MRC) Lung Cancer Working Party
(Hopwood et al., 1994), conclusions are reached only when
consistency among results is seen.
Patients and methods
Trial design and clinical investigations
From 1984 to 1989, the Swiss Group for Clinical Cancer
Research (SAKK) conducted a multicentre, randomised,
phase III trial in 406 eligible patients with SCLC testing
the principles of early vs late alternating chemotherapy.
Regimen A was PAV (cisplatin, adriamycin, VP 16-213).
Regimen B was CyMOC (cyclophosphamide, methotrexate,
oncovin, CCNU). Cycles were repeated as 'fast' as possible.
Patients were stratified according to stage (limited vs
extensive disease), performance status (0-1 vs 2-3) and
weight loss (<5% vs >5% of body weight) during the
previous 6 months. They were randomised to receive six
cycles of either ABABAB (early-alternating chemotherapy) or
AAABBB (late-alternating chemotherapy). The choice of
antiemetics was free. Response to treatment was assessed
according to WHO guidelines (World Health Organization,
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1979). The collection of QL data was planned prospectively
and included as an integral part of the trial (Hiirny et al.,
1992). The results of the trial, focusing on treatment
comparison, have been published elsewhere (Joss et al.,
1995b), including prevalence of patient-rated symptoms and
QL by treatment. Patients treated with early-alternating
chemotherapy rated their tumour symptoms, functional
status, fatigue/malaise and restrictions in social activities
significantly better, suggesting a better subjective adjust-
ment.
Quality of life assessment
For logistic reasons QL evaluation was planned only at eight
main centres (Hiirny et al., 1992). QL assessments were
scheduled at baseline (before start of chemotherapy) and
before administration of each of the six cycles of
chemotherapy. They were stopped if the patient went off
study. Patients were asked by the nurse to fill in the QL
questionnaire at the hospital and, if necessary, were given
assistance in completing it.
The QL questionnaire included three independent self-
rating instruments:
(1) Tumour symptoms, side-effects and various aspects of
physical, emotional and social functioning were assessed
with an early version of the EORTC questionnaire,
including lung cancer-specific items (Aaronson et al.,
1987). Reliability and validity criteria were tested and
confirmed overall and separately for the three languages
of the sample, i.e. German, French and Italian (Bernhard,
1992).
(2) As a reference scale, the Bf-S, a 28-item, one-dimensional
adjective checklist for emotional well-being, was included
(Von Zerssen, 1986). It was developed for serial
assessments in longitudinal psychopharmacological stu-
dies, and has become a standard measure in different
clinical settings.
(3) As a global indicator for general well-being, a single-item,
linear analogue self-assessment (LASA) scale was used
(Bernhard, 1992).
For this analysis we prospectively selected four scales that
represent general measures of well-being and functioning.
These measures were shown to be related to specific patient-
rated symptoms of both disease and treatment (Bernhard,
1992):
* Fatigue and malaise (subscale of early EORTC ques-
tionnaire): five items in a four-point scale format ('not at
all/a little/quite a bit/very much') with time frame related
to the past week.
* Personal functioning (subscale of early EORTC ques-
tionnaire): six items for self-care, mobility and physical
activity in a 'yes/no' response format with time frame not
specified.
* Emotional well-being (Bf-S adjective checklist): in accor-
dance with the prior use of the Bf-S, the time frame was
related to the 'present state or the way you feel now'.
* General well-being (LASA indicator): the time frame was
related to the 'last 4 weeks'.
The personal functioning and the fatigue/malaise scale
were summarised by mean values and linearised on a scale
from 0 to 100, as suggested by the EORTC QL Working
Group for the EORTC QLQ-C30 (EORTC Quality of Life
Study Group, 1995). In the present analysis, higher scores
indicate worse QL in all scales. Median scores were
rounded to the nearest integer value in the results
presentation.
The initial assessment represented a true baseline without
intervening treatment effects. For subsequent cycles, a time
window was allowed around planned assessment points (i.e.
beginning of each chemotherapy cycle). According to the
protocol, cycles were repeated as fast as possible without
fixed intervals. As a result of this, the sequence of QL forms
did not represent the exact time since randomisation but only
subsequent serial assessments.
Statistical methods
The pattern of change in QL data is difficult to analyse
(Hopwood et al., 1994). QL assessments result in several data
points for each patient, and multiple analyses may result in
invalid conclusions (Fletcher et al., 1992). One technique for
dealing with longitudinal data is repeated measure analysis
(Davis, 1991), which requires complete and normally
distributed data sets. In order to detect even moderate
differences, large sample sizes are necessary. In the present
study, only few patients had a complete set of assessments.
As an alternative to repeated measure analysis, we d,fined
summary measures (Matthews, 1993) and explored consis-
tency among related subgroups and concepts.
Three different analyses were performed:
(1) Overall sample. The aim was to use all available
information at any time point. As a summary measure
for 'overall QL' we defined the average score over six
cycles; all available scores were summarised by mean
values separately for each scale and patient. The relative
impact of prognostic and clinical variables was investi-
gated in multiple regression analyses (Neter et al., 1985).
(2) Limited sample (with baseline QL). Baseline QL scores
may predict the level of subsequent scores, and are
therefore relevant for investigating changes. We consid-
ered the subsample of all patients with baseline and at
least one subsequent QL assessment. The influence of
initial prognostic factors on baseline QL was investigated
by multiple regression analyses; their relevance was
estimated by the proportion of explained variance (R2).
In addition, we defined three summary measures of
change: (a) difference between baseline and worst
subsequent QL score as a measure for the 'minimum'
improvement (MIN) within the observation period; (b)
difference between baseline and best subsequent QL score
as a measure of the 'maximum' improvement (MAX)
within this period; and (c) difference between baseline and
last available QL score (Tandon, 1990) as an additional
liberal estimate of final' improvement (FIN) as a result of
treatment. These summary measures were calculated for
each patient and the 'paired' Wilcoxon signed-rank test
was used to test the hypothesis of no change (Siegel,
1956). The Wilcoxon rank-sum test was used to compare
QL scores according to levels of prognostic and clinical
factors (Siegel, 1956). The relative impact of prognostic
variables on the summary measures was investigated with
multiple regression analyses, adjusting for treatment and
response.
(3) Pattern of QL over cycles (graphical representation). For
each scale, the mean scores for subgroups ofpatients with
baseline and different numbers of subsequent forms were
checked and plotted. If these 'exploratory plots' appeared
consistent, we combined the data to examine descriptively
patterns ofQL over cycles. Median scores were connected
through time points to facilitate visual comparison. No
paired comparison was performed because of the different
patients contributing data at each assessment point.
Statistical tests for homogeneity of these plots are not
available.
The distribution of patient characteristics in the overall
and limited samples was compared using the chi-square test.
The initial prognostic factors were treated as categorical,
including gender (female vs male), age (<60 vs >60 years),
initial tumour stage (limited vs extensive disease), WHO
performance status (0-1 vs 2-3) and previous weight loss
(<5% vs >5%). Serial measures of performance status were
not considered. The clinical variables included treatment arm
(early vs late alternating) and clinical response (partial/
complete vs no change/progression). Missing QL values were
not replaced by assigned values.
All P values were derived from two-sided significance tests.
Because of the exploratory approach resulting in multiple
testing, the interpretation of P values changes. Our findings
should be confirmed in other studies.Prognostic factors and quality of life in SCLC
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Results
Patient characteristics and QL compliance
As detailed elsewhere, the average rate of returned
questionnaires with an exact timing over the six cycles was
49% (Hurny et al., 1992). With the extended time window,
54-56% of expected scale scores were available. The
subgroup with QL data was compared with the one without
and no significant differences were found regarding
biomedical data (Bernhard, 1992). The number of evaluable
patients/assessments differed between the four scales (Tables I
and II). The overall and limited samples had a similar
distribution of patient characteristics; the two treatment
groups were balanced.
Overall sample
Levels of initial tumour stage, performance status and weight
loss discriminated the average scores of each scale during all
cycles. Patients with poor prognostic factors reported worse
scores (i.e. higher scores), as shown for emotional well-being
(Bf-S) in Figure 1.
The summary measure for 'overall' QL was also predicted
in all scales by initial prognostic factors in multivariate
analyses (Table I). Older patients reported worse fatigue/
malaise. Patients with extensive disease reported worse
general and emotional well-being. Those with greater weight
loss reported worse fatigue/malaise and general well-being.
Those with poor performance status reported worse fatigue/
malaise, personal functioning and emotional well-being.
Limited sample (with baseline QL)
Baseline QL according to prognostic factors Baseline
differences, according to the level of initial prognostic
factors, were present in all scales. Patients with poor
prognostic factors reported worse baseline QL scores (Table
II; note that the subgroups 'females' and 'performance status
2-3' include very few patients). Significant differences were
seen by tumour stage for personal functioning (median
values, 0 vs 25 for limited vs extensive disease) and
emotional well-being (median values, 6 vs 18 for limited vs
extensive disease). According to weight loss, there were
significant differences for fatigue/malaise (median values, 40
Table I Overall sample: patient characteristics and predictive value of prognostic factors for 'overall' QL (multiple regression analyses)a,b
Personal General well- Emotional well-
N for Fatigue/malaise functioning being (LASA) being (Bf-S)
fatiguel coefficient (s.e.) coefficient (s.e.) coefficient (s.e.) coefficient (s.e.)
malaise (N= 124; n=444)c (N= 130; n=459)c (N = 125; n=440)c (N= 127; n=453)c
Sex
Female
Male
Age (years)
<60
) 60
Tumour stage
Limited
Extensive
Weight loss
<5%
>5%
12 (10%)
112 (90%)
68 (55%)
56 (45%)
41 (33%)
83 (67%)
81 (65%)
43 (35%)
-1.46 (2.5)
7.26 (1.48)
1.83 (1.54)
7.59 (1.65)
-1.18 (6.6)
0.82 (3.9)
7.82 (4.16)
5.63 (4.21)
0.39 (8.10)
0.65 (4.85)
12.04 (5.06)
13.26 (5.14)
1.28 (3.2)
0.59 (1.94)
4.11 (2.04)
3.53 (2.05)
Performance status
0-1 107(87%) - -
2-3 17 (13%) 9.64 (2.31) 14.62 (5.59) 4.62 (6.94) 6.4 (2.7)
aBold values indicate P<0.05. bModels adjusted for treatment arm, tumour response, language. cN=total number ofpatients; n =total number
of assessments.
Table II Limited sample: patient characteristic and baseline QLa
Personal General well- Emotional well-
Fatigue/malaise functionink being (LASA) being (Bf-S)
(O-100) (0-100) (O-100)b (-56)
N Median N Median N Median N Median
Sex
Female 6 57 5 50 4 26 6 14
Male 43 47 48 17 47 51 45 12
Age (years)
<60 30 47 32 17 30 53 31 11
._60 19 47 21 17 21 50 20 20
Tumour stage
Limited 19 40 19 0 18 44 20 6
Extensive 30 53 34 25 33 52 31 18
Weight loss
<5% 29 40 33 17 34 47 32 10
> 5% 20 60 20 17 17 63 19 13
Performance status
0-1 42 40 46 17 44 50 45 11
2-3 7 63 7 83 7 100 6 34
aBold values indicate P<0.05 (Wilcoxon rank-sum test). bFull-scale (lower values indicate better QL).vs 60 f
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for <5% vs >5% weight loss) and general well-being 'Minimal', 'maximum' and final' improvement in QL under
tn values, 47 vs 63 for <5% vs >5% weight loss). chemotherapy In the subsample of patients with baseline
mance status had a significant impact on all scales at and at least one subsequent QL assessment, we observed an
ie. The proportion of variance in baseline scores overall improvement (i.e. subsequent scores were significantly
ned by these prognostic factors was 22% for fatigue/ lower than baseline scores) in all scales except for personal
,e and 33-35% for the other scales. functioning, as summarised in Table III (overall; see last
row). The improvements were most pronounced in general
well-being. The range of improvements is described approxi-
mately by the range between MIN and MAX. As an
example, the improvement in general well-being ranged
between -7 (MIN) and -43 (MAX).
i6 - Tumour stage: Limited In this group ofpatients, we compared the three summary
18 - ---- Extensive measures (MAX, MIN, FIN) by levels of prognostic factors
separately for each scale. In general, the improvement was
greater in patients with poor prognostic factors (Table III;
P4 - note that the subgroups 'females' and 'performance status 2-
16- ----- -------~~~~~F~~~~~~It~~~ ~ -------3' include very few patients). In detail, patients with extensive
8 + | I l | disease showed a significantly greater improvement in
o 1 personal functioning (MAX= - 17) than those with limited
2 3Cyl 4 5 6 disease (MAX=O). Patients with >,5% weight loss showed a
significantly larger improvement in fatigue/malaise
;6 - Performance status: - 0-1 (MIN = -7) than those with weight loss <5% (MIN =7)
W8 ---- 2-3 and a much larger improvement in general well-being (see
to _ MAX, MIN, FIN in Table III). Patients with poor
32 P >> |------ 2 performance status had a larger improvement in fatigue/
24 "^sv ,,,-- -- malaise (MAX = - 13 vs -33 for performance status 0-1 vs
16_-_______ _l_l 2-3, in personal functioning (all MAX, MIN, FIN) and
8 -_ emotional well-being (MAX= -5 vs -22 for performance
o status 0- 1 vs 2-3). Figure 2 shows the maximum
2 3 Cce4 5 6 improvement of general well-being by weight loss and
Cycle personal functioning by performance status.
56 - Weight loss: <5% The results of the three summary measures were confirmed
t8 -
---- >,5% by multivariate analyses, as summarised in Table IV for
to - 'maximum' improvement. A different finding concerned
32 - weight loss: patients with a previously higher weight loss
24 reported a deterioration in emotional well-being. The
16 ----- - --- predictive value of performance status was confirmed for
8 _ -i - - personal functioning and general and emotional well-being.
O In addition, male patients reported better general well-being
1 2 3 4 5 6 and older patients reported worse general well-being.
Cycle
Figure 1 Overall sample: emotional well-being (Bf-S) over six
cycles by levels of initial prognostic factors (±2s.e.). Average
scores are connected through time points to facilitate visual
comparisons; they are based on different sample sizes.
Pattern of QL over cycles (graphical representation)
In the graphical representation patients with poor initial
prognostic factors again showed worse QL. Those with
Table III Limited sample: 'minimum', 'maximum' and 'final' improvement in QL during chemotherapy (medians)a
Personal General well-being Emotional well-being
Fatigue/malaise functioning (LASA) (Bf-S)
(0-100)b (O 100) (O-100)b (f-56)
N=49 N=53 N=51
MIN MAX FIN MIN MAX FIN MIN MAX FIN MIN MAX FIN
Sex
Female 17 -23 -7 0 -50 -50 25 -8 24 -2 -6 -6
Male 0 -13 -7 0 0 0 -22 -44 -36 1 -5 -3
Age (years)
<60 0 -10 -7 0 0 0 -26 -43 -38 1 -5 -3
>60 0 -13 -7 0 -17 0 0 -43 -16 0 -6 -4
Tumour stage
Limited 0 -13 -7 0 0 0 -2 -34 -17 1 -5 -2
Extensive 0 -13 -7 0 -17 -8 -22 -45 -36 0 -6 -6
Weight loss
<5% 7 -13 -7 0 0 0 -1 -37 -15 0 -5 -3
, 5% -7 -20 -10 0 -8 -8 -36 -49 -44 2 -6 -4
Performance status
0-1 0 -13 -7 0 0 0 -5 -37 -25 0 -5 -3
2-3 7 -33 -27 -50 -50 -50 -45 -48 -45 -8 -22 -15
Overallc 0 -13 -7 0 0 0 -7 43 -33 0 -5 4
aBoldvalues indicate P<0.05 (Wilcoxon rank-sumtest); negative values indicate improvement.
bFull scale range. cBold values indicate P<0.05
(Wilcoxon signed-rank test).
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extensive disease reported worse general well-being over all
cycles, as shown in Figure 3a. During the first two cycles
only, they reported worse fatigue/malaise and personal
functioning, indicating an early and unstable difference. A
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greater weight loss had an adverse impact on fatigue/malaise,
personal functioning and emotional well-being over all cycles
(Figure 3b). Similarly, those with poor performance status
reported worse scores in all scales over this period, as shown
a
Extensive
2 4 6
Cycle
50
40
mI
30
20
10
0
0-1 2-3
Levels of performance status
Figure 2 Limited sample: box plots of 'maximum' improvement
in general well-being (LASA) by level of previous weight loss (a)
and of personal functioning (PF) by performance status (b). The
line in the middle of the box represents the median; the box
extends from the 25th to the 75th percentile.
b
<5%
-,
1 2 3 4 5 6
Cycle
Figure 3 Limited sample: general well-being (LASA) over cycles
by levels of initial stage (a) and emotional well-being (Bf-S) over
cycles by levels of previous weight loss (b). Median scores are
connected through time points to facilitate visual comparisons;
they are based on different sample sizes.
Table IV Limited sample: predictive value of prognostic factors for 'maximum' improvement in QL (multiple regression analyses)a,b
Personal General well- Emotional well-
Fatigue/malaise functioning being (LASA) being (Bf-S)
coefficient (s.e.) coefficient (s.e.) coefficient (s.e.) coefficient (s.e.)
(N=48) (N= 52) (N 50) (N 50)
Sex
Female
Male -7.57 (10.52) -15.71 (12.14) -46.98 (19.63) 1.21 (5.47)
Age (years)
<60 -
) 60 6.32 (7.42) 2.73 (7.48) 24.47 (11.20) 0.21 (3.90)
Tumour stage
Limited
Extensive -4.46 (7.11) -7.45 (7.32) -4.64 (10.68) -5.90 (3.65)
Weight loss
<5%
k5% -12.72 (7.69) 10.10 (8.17) -14.97 (11.20) 8.80 (3.79)
Performance status
0-1
2-3 3.69 (10.73) -39.80 (11.35) -39.57 (16.59) -13.69 (5.76)
aBold values indicate P<0.05;negative values indicate improvement.
bModelsadjusted for tumour response; fatigue/malaise also for treatment
(significant effect).
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Figure 4 Limited sample: general well-being (LASA; a) and
emotional well-being (Bf-S; b) over cycles by levels of
performance status. Median scores are connected through time
points to facilitate visual comparisons; they are based on different
sample sizes.
in Figure 4 for general and emotional well-being. Older
patients reported worse fatigue/malaise and general well-
being. In addition, they showed a tendency to improve later
than younger patients.
In summary, in all three analyses the differential impact of
initial tumour stage, weight loss and performance status was
consistently confirmed; levels of performance status and
weight loss discriminated QL the most. Patients with poor
initial prognostic factors reported worse baseline QL and
showed a greater improvement under treatment. However, in
general, their scores did not reach the values of those with
good prognostic factors.
Discussion
Do initial prognostic factors predict QL during chemother-
apy in patients with SCLC? In clinical experience, there is
large variability in psychosocial adjustment of lung cancer
patients, related to the course of disease and treatment. A
positive relationship has been described between QL and
good physical functioning as well as limited disease (Ganz et
al., 1992).
As expected, in the present study, those patients with poor
prognostic factors at diagnosis consistently reported worse
QL at baseline than those with good prognostic factors. A
similar association between the patients' performance status,
extent of disease and psychological distress, as measured by
the Profile of Mood States (POMS; McNair et al., 1971), has
been reported in a randomised trial including over 400 SCLC
patients (Cella et al., 1987). In this study, physical
impairment showed an approximately linear relationship to
increasing levels of psychological distress at baseline but
accounted for a smaller amount of the variability in mood
disturbance (10-15%) than the present data.
Correspondingly, given the high response rates, a
substantial improvement in QL under chemotherapy is
expected, particularly in patients with poor initial prognostic
factors. Our findings support this assumption: patients with
poor initial prognostic factors showed the most pronounced
improvement in QL under cytotoxic treatment. A similar
improvement within the first three chemotherapy cycles has
recently been shown in another SCLC trial (Wolf et al.,
1991). Chemotherapy can be helpful in adjusting to diagnosis,
as tumour response to treatment improves physical
performance and alleviates symptoms (Bleehen et al., 1993).
The question remains, however, whether QL is further
improving after response in these patients with extensive
disease and resulting in scores similar to those in patients
with good prognostic factors.
After controlling for tumour response, and despite the
substantial improvement reflected in the change of QL
measures, patients with poor initial prognostic factors
reported worse scores over cycles and generally did not
reach the level of the good risk patients.
In extensive-disease patients with primarily palliative
treatment, a cost-benefit estimate between survival/pallia-
tion and side-effects of treatment has to be performed. We
have recently reported a trial in extensive disease patients
comparing our standard regimen of cisplatin, doxorubicin
and etoposide alternating with cyclophosphamide, metho-
trexate, vincristine and lomustine with a mild treatment of
carboplatin and teniposide (Joss et al., 1995a). Contrary to
expectation, patients receiving the latter regimen had a
significantly lower remission rate and survival; the trial had
therefore to be closed prematurely. In this small trial,
physician and patient-rated side-effects were worse with the
standard regimen, but no difference was observed in patient-
rated tumour symptoms and general aspects of QL.
In a Cancer Research Campaign trial, 300 patients with
untreated limited and extensive SCLC and no progressive
disease affer the first cycle of cytotoxic treatment were
randomised to receive cyclophosphamide, vincristine and
etoposide either regularly 'planned' or given 'as required'
for tumour-related symptoms and progression of disease with
a maximum of eight cycles (Earl et al., 1991). Patients
receiving treatment 'as required' received on average half as
much chemotherapy, but did not show a significantly shorter
survival. However, in a subsample of 62 patients with QL
assessment, those with treatment as required scored more
severe symptoms than those receiving planned treatment.
Similar results have been reported in metastatic breast cancer
(Coates et al., 1987).
In addition to symptom alleviation, treatment is usually
associated with hope and supports particular patients in
coping with their anxiety of fatal outcome. However, the
optimal balance between treatment intensity, biomedical and
QL outcome needs further specification. According to the
present knowledge and our data, patients with limited disease
benefit subjectively, in terms of their QL, from the currently
available, intensive and regularly scheduled, standard
chemotherapy regimens, as toxic side-effects are largely
outweighed by improvement of tumour-related symptoms
and therefore general well-being. These patients should be
treated accordingly.
In patients with extensive disease, especially the elderly,
the choice of treatment is more difficult. As their QL is
substantially improving, mainly during the first three
treatment cycles, but does not reach the level observed in
limited-disease patients even after response, a conceivable
treatment option could be to treat these patients intensively
to maximum response and to continue with a milder
maintenance therapy including best supportive care. This
option has to be tested in a randomised clinical trial against
intensive standard chemotherapy, as used for patients with
limited disease.
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In the present analysis, we have chosen four QL measures
sensitive to both disease symptoms and treatment side-effects
and giving an overall estimation of patients' physical and
psychological well-being (Bernhard, 1992). All were sensitive
to initial prognostic factors but showed distinct patterns,
which may be explained by their different concepts and time
frames. As in other QL trials in SCLC patients (Bleehen et
al., 1989, 1993; Gower et al., 1995), missing data limit this
analysis, although summary measures revealed consistent
findings among related subgroups and concepts. As drop-out
rates increased with time, data were collected only from
patients with a better health status. Thus, analyses ofchanges
in QL may show, to a certain extent, an attrition bias (i.e.
rapidly diminishing patient numbers). In addition, only major
differences could be demonstrated owing to the small sample
size and related reduced statistical power.
The potential underlying interactions between prognostic
factors, treatment, course of disease and patient's adjustment
process need further study, including improved methods for
handling missing data and longitudinal analyses. Clinically, a
high-risk group for poor adjustment is of particular concern,
as suggested by a screening trial for psychological morbidity
in advanced SCLC (Hopwood and Thatcher, 1990). In
addition, patients with poor performance status may find it
too burdensome to participate actively in the treatment
decision (Blanchard et al., 1988).
In conclusion, initial tumour stage, performance status
and previous weight loss can predict QL during chemother-
apy, even after controlling for response to treatment. To
determine the optimal balance between treatment intensity,
efficacy and QL in SCLC remains a challenge. Prognostic
factors for psychosocial outcome should be investigated
further, possibly providing additional information for the
difficult decision of how to treat SCLC patients with
extensive disease.
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